Practical use of Adenoprosin® in combination therapy in men with lower urinary tract symptoms
- Authors: Kasyan G.R.1,2, Khodyreva L.A.2, Grigoryan B.L.1, Dyakov V.V.1,2
-
Affiliations:
- FGBOU VO “Russian University of Medicine”
- Moscow Urologic Center, S.P. Botkin’s State Clinical Hospital
- Issue: No 1 (2024)
- Pages: 61-70
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/630546
- DOI: https://doi.org/10.18565/urology.2024.1.61-70
- ID: 630546
Cite item
Open Access
Access granted
Abstract
Aim. The aim of the observational cohort study is to study and evaluate the efficiency of the drug Adenoprosin® in combination with other drugs in comparison with monotherapy.
Materials and methods. Data from 6,442 patients at 221 medical institutions in 39 cities from November 2020 to December 2022 were analyzed. The drug Adenoprosin® in the form of rectal suppositories was prescribed as monotherapy in group I, while patients in group II received Adenoprosin® in a combination with other drugs. The efficacy of treatment was assessed using uroflowmetry data, prostate volume, postvoid residual volume and validated scales (NIH-CPSI, IIEF-5, IPSS, QoL).
Results. The diagnosis was validated in 6375 cases, including BPH (n=1498), chronic prostatitis (CP; n=3060), and in combination of both disorders (n=1817). A total of 3580 patients received Adenoprosin® as monotherapy, while 2761 received combination therapy. In most cases, a combination therapy was prescribed in case of more severe disease. In patients with BPH, positive changes after treatment were noted in favor of group I according to change in postvoid residual volume (p<0.001) and prostate volume (p<0.001). Combination therapy demonstrated significant positive changes compared with monotherapy when assessing NIH-CPSI scores (p=0.005), IPSS scores (p<0.001) and the mean maximum urine flow rate (Qmax; p<0.001). Qmax increased significantly in both groups (from 14 ml/s to 17 ml/s in group I and from 12 ml/s to 14 ml/s in group II).
Conclusion. Treatment of BPH, CP and their combination is a complex clinical task. The multiple nature of complaints often dictates the need for simultaneous administration of two or more drugs. Combination therapy involves the use of multiple therapeutic strategies to treat different aspects of BPH and CP.
In patients with BPH, a combination therapy has been shown to be more effective than monotherapy with either class of drugs, as it reduces the risk of disease progression, acute urinary retention, and the need for surgery. However, combination therapy should be considered on an individual basis, taking into account symptoms, prostate size and overall health. There is no universal treatment method for BPH suitable for any patient. The treatment strategy should be chosen individually, considering all medical and social factors.
All of the above applies to a large extent to the treatment of CP and CP + BPH. According to our results, Adenoprosin® demonstrated efficacy both as monotherapy and in combination with other traditional drugs in the treatment of men with lower urinary tract symptoms.
Keywords
Full Text
About the authors
G. R. Kasyan
FGBOU VO “Russian University of Medicine”; Moscow Urologic Center, S.P. Botkin’s State Clinical Hospital
Author for correspondence.
Email: g.kasyan@outlook.com
Ph.D., MD, professor at the Department of Urology of FGBOU VO “Russian University of Medicine”, Head of the Urologic Department of S.P. Botkin’s State Clinical Hospital
Russian Federation, Moscow; MoscowL. A. Khodyreva
Moscow Urologic Center, S.P. Botkin’s State Clinical Hospital
Email: g.kasyan@outlook.com
Ph.D., MD, Moscow Urologic Center, S.P. Botkin’s State Clinical Hospital
Russian Federation, MoscowB. L. Grigoryan
FGBOU VO “Russian University of Medicine”
Email: g.kasyan@outlook.com
Department of Urology of FGBOU VO “Russian University of Medicine”
Russian Federation, MoscowV. V. Dyakov
FGBOU VO “Russian University of Medicine”; Moscow Urologic Center, S.P. Botkin’s State Clinical Hospital
Email: g.kasyan@outlook.com
Department of Urology of FGBOU VO “Russian University of Medicine”, Moscow, Russia; Moscow Urologic Center, S.P. Botkin’s State Clinical Hospital
Russian Federation, Moscow; MoscowReferences
- Egan K.B. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. The Urologic clinics of North America. 2016;43(3):289–297. https://doi.org/10.1016/j.ucl.2016.04.001
- Gratzke C., Bachmann A., Descazeaud A., Drake M.J., Madersbacher S., Mamoulakis C., Oelke M., Tikkinen K.A.O., Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. European urology. 2015;67(6):1099–1109. https://doi.org/10.1016/j.eururo.2014.12.038
- Rees J., Abrahams M., Doble A., Cooper A. Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU International. 2015;116(4):509–525. https://doi.org/10.1111/bju.13101
- Chung S.D., Keller J.J., Lin H.C. A case-control study on the association between chronic prostatitis/chronic pelvic pain syndrome and erectile dysfunction. BJU International. 2012;110(5):726–730. https://doi.org/10.1111/j.1464-410X.2011.10807.x
- Lerner L.B., McVary K.T., Barry M.J., Bixler B.R., Dahm P., Das A.K., Gandhi M.C., Kaplan S.A., Kohler T.S., Martin L., Parsons J.K., Roehrborn C.G., Stoffel J.T., Welliver C., Wilt T.J. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. J Urol. 2021;206(4):806–817. https://doi.org/10.1097/JU.0000000000002183
- Kasyan G.R., Khodyreva L.A., Dudareva A.A., Tupikina N.V., Pushkar D.Y. Combined treatment of lower urinary tract symptoms in men. Medical advice. 2016;5:84–90. Russian (Касян Г.Р., Ходырева Л.А., Дударева А.А., Тупикина Н.В., Пушкарь Д.Ю. Комбинированное лечение симптомов нижних мочевых путей у мужчин. Медицинский совет. 2016;5:84–90).
- Kasyan G.R., Konovalov I.V. Modern possibilities of combined therapy of lower urinary tract symptoms against the background of benign prostatic hyperplasia in men. Research and practice in medicine. 2016;3(2):37–44. Russian (Касян Г.Р., Коновалов И.В Современные возможности комбинированной терапии симптомов нижних мочевыводящих путей на фоне доброкачественной гиперплазии предстательной железы у мужчин. Исследования и практика в медицине. 2016;3(2):37–44).
- Kim B.S., Ko Y.H., Song P.H., Kim T.H., Kim K.H., Kim B.H. Prostatic urethral length as a predictive factor for surgical treatment of benign prostatic hyperplasia: a prospective, multiinstitutional study. Prostate international. 2019;7(1):30–34. https://doi.org/10.1016/j.prnil.2018.06.002
- Filimonov V.B., Vasin R.V., Sobennikov I.S., Shirobakina E.Yu. Conservative treatment of lower urinary tract symptoms in benign prostatic hyperplasia. Bulletin of Pirogov National Medical & Surgical Center. 2020;15(4):102-106. https://doi.org/10.25881/BPNMSC.2020.54.45.019 Russian (Филимонов В.Б., Васин Р.В., Собенников И.С., Широбакина Е.Ю. Консервативное лечение симптомов нижних мочевых путей при доброкачественной гиперплазии предстательной железы. Вестник НМХЦ им. Н.И. Пирогова. 2020;15(4):102–106. https://doi.org/10.25881/BPNMSC.2020.54.45.019).
- Kruep E.J., Hogue S.L., Eaddy M.T., Chandra M.D. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. P & T : a peer-reviewed journal for formulary management. 2021;36(8):493–507.
- Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Entomological drug adenosine for the treatment of patients with benign prostatic hyperplasia and chronic prostatitis. Urologiia. 2021;1:39–44. Doi: https://dx.doi.org/10.18565/urology.2021.1.39-44. Russian (Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Энтомологический препарат аденопросин в лечении пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2021;1:39–44. DOI: https://dx.doi.org/10.18565/urology.2021.1.39-44).
- Medvedev V.L., Efremov M.E. The effectiveness of the drug Adenoprosin® in the complex treatment of patients with chronic bacterial prostatitis. Innovative medicine of Kuban. 2020;3(19):45–51. Russian (Медведев В.Л., Ефремов М.Е. Эффективность применения препарата Аденопросин® в комплексном лечении пациентов с хроническим бактериальным простатитом. Инновационная медицина Кубани. 2020;3(19):45–51).
- Demidko Yu.L., Allenov S.N., Uzhegov T.A., Kasiteridi I.G. The effectiveness of Adenoprosine in patients with benign prostatic hyperplasia, chronic prostatitis and lower urinary tract symptoms. Effective pharmacotherapy. 2021;17(3):34–41. Russian (Демидко Ю.Л., Алленов С.Н., Ужегов Т.А., Каситериди И.Г. Эффективность Аденопросина у пациентов с доброкачественной гиперплазией предстательной железы, хроническим простатитом и симптомами нижних мочевых путей. Эффективная фармакотерапия. 2021;17(3):34–41).
- Al-Shukri A.S., Kostyukov S.V., Maksimova A.V. Efficacy evaluation of entomological drug Adenoprosin® usage in combined treatment of patients with lower urinary tract symptoms due to benign prostate enlargement. Urology reports (St.-Petersburg). 2021;11(4):337–344. doi: 10.17816/uroved89410. Russian (Аль-Шукри А.С., Костюков С.В., Максимова А.В. Оценка эффективности применения энтомологического препарата «Аденопросин®» в комбинированной терапии пациентов с симптомами нижних мочевых путей, обусловленных доброкачественным увеличением предстательной железы. Урологические ведомости. 2021;11(4):337–344. doi: 10.17816/uroved89410).
- Kyzlasov P.S., Abuev G.G., Mustafaev A.T. Evaluation of the efficacy and safety of Adenoprosin® in patients with category IIIA chronic prostatitis. Experimental and Clinical Urology 2023;16(1):108-114; https://doi.org/10.29188/2222-8543-2023-16-1-108-114. Russian (Кызласов П.С., Абуев Г.Г., Мустафаев А.Т. Оценка эффективности и безопасности препарата Аденопросин® у пациентов с хроническим простатитом IIIA категории. Экспериментальная и клиническая урология. 2023;16(1):108-114. https://doi.org/10.29188/2222-8543-2023-16-1-108-114).
Supplementary files
